Abstract:Background Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by irreversible joint destruction and disability. At present, the biggest challenge in the field of RA treatment is the emergence of multidrug resistance (MDR) in the application of disease-modifying anti-rheumatic drugs (DMARDs).The Multidrug resistance Related Protein and Multi Drug Resistance protein 1, also called P-glycoprotein can decreases the intracellular concentration of different drugs. Moreover, cytokines play an increasingly important role in the expression regulation mechanisms of P-gp, especially inflammatory cytokines IL-6. Previously, We have indicated that Interleukin-6 up-regulates P-gp in peripheral blood lymphocytes via the JAK2-STAT3 pathway in RA patients. Through more than ten-years9 clinical research, we observed that the therapeutic cycle alliance of methotrexate (MTX) and cyclophosphamide (CTX) has had better curative effect and lower rate of adverse reaction in treating RA. And we didn9t found the emergence of MDR. How can the therapeutic alliance of MTX and CTX overcome MDR in RA patients? This study will give the answer. Objectives To Clarify whether the therapeutic alliance of MTX and 4-hydroperoxycyclophosphamide (4-HC) suppress expression and mRNA of P-gp in peripheral blood lymphocytes of RA through JAK2-STAT3 pathway. Methods RA patients without any DMARDs and biologic therapy (n=15) were enrolled. P-gp expression level was detected by Flow Cytometry. P-gp mRNA of peripheral blood lymphocytes and the intracellular signaling pathway mediating the effects of MTX and 4-HC on IL-6-stimulated JAK2-STAT3 activation was assessed by RT-PCR. Results Compared with blank control group, IL-6 induced P-gp, JAK2 and STAT3 expression levels increased significantly ( P P P u003e0.05). Conclusions Our data indicated that MTX combined with CTX significantly inhibited IL-6 induced JAK2-STAT3 activation, as well as the induction of P-gp. Inhibition of IL-6-mediated multidrug resistance signaling pathways by the alliance of MTX and CTX may represents a new reversing drug-resistance therapeutic strategy for RA. References Li HX, Zhao W, Shi Y, et al. Retinoic acid amide inhibits JAK/STAT pathway in lung cancer which leads to apoptosis. Tumour Biol. 2015; 36(11): 8671–8678. Oh HM, Lee SW, Yun BR, et al. Vigna angularis inhibits IL-6-induced cellular signalling and ameliorates collagen-induced arthritis. Rheumatology (Oxford). 2014; 53(1): 56–64. Li R, Cai L, Ren DY, Xie XF, Hu CM, Li J. Therapeutic effect of 7, 39-dimethoxy hesperetin on adjuvant arthritis in rats through inhibiting JAK2-STAT3 signal pathway. Int Immunopharmacol. 2012; 14(2): 157–163. Yun M, Lee D, Park MN, et al. Cinnamaldehyde derivative (CB-PIC) sensitizes chemo-resistant cancer cells to drug-induced apoptosis via suppression of MDR1 and its upstream STAT3 and AKT signalling. Cell Physiol Biochem. 2015; 35(5): 1821–1830. Disclosure of Interest None declared

Methotrexate and Triptolide regulate Notch signaling pathway by targeting the Nedd4-Numb axis

Triptolide affects the differentiation, maturation and function of human dendritic cells.

Triptolide Inhibits the Proliferation of Cells from Lymphocytic Leukemic Cell Lines in Association with Downregulation of NF-κB Activity and Mir-16-1*.

Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 expression through PI3-K/Akt and NF-κB pathways

AB0100 Mtx combined with ctx inhibited il-6 induced jak2-stat3 activation and the induction of p-gp in peripheral blood lymphocytes of rheumatoid arthritis patients

Triptolide Enhances the Sensitivity of Multiple Myeloma Cells to Dexamethasone Via Micrornas.

Identification of an exosomal miRNA-mRNA regulatory network contributing to methotrexate efficacy

Methotrexate Neurotoxicity Is Related to Epigenetic Modification of the Myelination Process

Tetramethypyrazine inhibits renal cell carcinoma cells through inhibition of NKG2D signaling pathways

Low dose methotrexate impaired T cell transmigration through down-regulating CXCR4 expression in rheumatoid arthritis (RA)

Tumor cell–derived microparticles induced by methotrexate augment T-cell antitumor responses by down-regulating expression of PD-1 in neutrophils

Association between high-dose methotrexate-induced toxicity and polymorphisms within methotrexate pathway genes in acute lymphoblastic leukemia

Methotrexate inhibits glucocorticoids-induced osteoclastogenesis via activating IFN-{gamma}R/STAT1 pathway in the treatment of rheumatoid arthritis

Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation

Notch-1 siRNA and Methotrexate towards a Multifunctional Approach in Rhematoid Arthritis Management: a Nanomedicine Approach

Methotrexate Attenuates the Th17/Il-17 Levels in Peripheral Blood Mononuclear Cells from Healthy Individuals and Ra Patients

Immunosuppressant triptolide inhibits dendritic cell-mediated chemoattraction of neutrophils and T cells through inhibiting Stat3 phosphorylation and NF-κB activation

Triptolide sensitizes cancer cells to nucleoside DNA methyltransferase inhibitors through inhibition of DCTPP1-mediated cell-intrinsic resistance

The interaction of methotrexate with the human C5a and its potential therapeutic implications

Immunosuppressant triptolide inhibits dendritic cell-mediated chemoattraction of neutrophils and T cells through inhibiting Stat3 phosphorylation and NF-kappaB activation.

[Therapeutic Effect and Impact on Cytokine Production by Methotrexate in Rheumatoid Arthritis].